EGFR and non-small cell lung carcinoma: We observed that 17-AAG, an HSP90 inhibitor targeting the NTD of ATP binding pocket, obviously downregulated expression of general clients, like EGFR, CDK4, and c-Raf1, in human NSCLC PC9, NCI-H1975, and A549 cells (Fig. 5e).